Login to Your Account



Alpharadin Heats Up Competition For Prostate Cancer Therapies

By Nuala Moran


Tuesday, September 27, 2011
LONDON – The competitive potential of Alpharadin in treating bone metastases in patients with hormone-resistant prostate cancer was underlined in the first formal presentation of the Phase III study results, which showed the alpha-emitting radiotherapy not only met the primary endpoint of overall survival, but also all secondary endpoints, including a reduction in the number of bone fractures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription